Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders

Clinica Chimica Acta

Volumn 438, Issue , 2015, Pages 35-42

  Kappelmayer, János ^a   Antal Szalmás, Péter ^a   Nagy Jr, Béla ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Algorithm; EGFR; HE4; Ovarian cancer; Prediction; Renal failure

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ALGORITHM; CANCER SURVIVAL; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; LABORATORY TEST; OVARY TUMOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; URINE LEVEL; FEMALE; METABOLISM; OVARIAN NEOPLASMS; URINE; ADULT; AGE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; PELVIC DISEASE; PREDICTION; PROBABILITY; SENSITIVITY AND SPECIFICITY; SMOKING; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX CANCER;

ALGORITHMS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; OVARIAN NEOPLASMS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906329955     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.07.040     Document Type: Review

References (79)

1. Seibaek L., Petersen L.K., Blaakaer J., Hounsgaard L. Symptom interpretation and health care seeking in ovarian cancer. BMC Womens Health 2011, 11:31.
2. Bristow R.E., Chang J., Ziogas A., Randall L.M., Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 2014, 132:403-410.
3. Bamias A., Karadimou A., Soupos N., et al. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience. Gynecol Oncol 2011, 123:37-42.
4. Menon U., Griffin M., Gentry-Maharaj A. Ovarian cancer screening-current status, future directions. Gynecol Oncol 2014, 132:490-495.
5. Poumpouridou N., Kroupis C. Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clin Chem Lab Med 2011, 50:423-434.
6. Hermsen B.B., Olivier R.I., Verheijen R.H., et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007, 96:1335-1342.
7. Hellström I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
8. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408.
9. Escudero J.M., Auge J.M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011, 57:1534-1544.
10. Lenhard M., Stieber P., Hertlein L., et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011, 49:2081-2088.
11. Hertlein L., Stieber P., Kirschenhofer A., et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med 2012, 50:2181-2188.
12. Bast R.C., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., Mills G.B. CA125: the past and the future. Int J Biol Markers 1998, 13:179-187.
13. Urban N., Thorpe J.D., Bergan L.A., et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 2011, 103:1630-1634.
14. Schummer M., Ng W.V., Bumgarner R.E., et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999, 238:375-385.
15. Wang K., Gan L., Jeffery E., et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999, 229:101-108.
16. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991, 45:350-357.
17. Bingle L., Singleton V., Bingle C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21:2768-2773.
18. Clauss A., Lilja H., Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002, 368:233-242.
19. Schalkwijk J., Wiedow O., Hirose S. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J 1999, 340:569-577.
20. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006, 19:847-853.
21. Paek J., Lee S.H., Yim G.W., et al. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2011, 158:338-342.
22. Moore R.G., McMeekin D.S., Brown A.K., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46.
23. Huhtinen K., Suvitie P., Hiissa J., et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009, 100:1315-1319.
24. Nolen B., Velikokhatnaya L., Marrangoni A., et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010, 117:440-445.
25. Moore R.G., Miller M.C., Steinhoff M.M., et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 2012, 206(351):e1-e351. [e8].
26. Anastasi E., Marchei G.G., Viggiani V., Gennarini G., Frati L., Reale M.G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010, 31:113-119.
27. Speeckaert M.M., Speeckaert R., Delanghe J.R. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem 2013, 59:1-21.
28. Ferraro S., Braga F., Lanzoni M., Boracchi P., Biganzoli E.M., Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol 2013, 66:273-281.
29. Ruggeri G., Bandiera E., Zanotti L., et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011, 412:1447-1453.
30. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.G. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990, 97:922-929.
31. Macuks R., Baidekalna I., Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumour Biol 2012, 33:1811-1817.
32. Moore R.G., Jabre-Raughley M., Brown A.K., et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010, 203(228):e1-e6.
33. Montagnana M., Danese E., Ruzzenente O., et al. The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med 2011, 49:521-525.
34. Andersen M.R., Goff B.A., Lowe K.A., et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010, 116:378-383.
35. Van Gorp T., Veldman J., Van Calster B., et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer 2012, 48:1649-1656.
36. Trapé J., Filella X., Alsina-Donadeu M., et al. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011, 49:1605-1620.
37. Bouchard D., Morisset D., Bourbonnais Y., Tremblay G.M. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006, 7:167-174.
38. Lu R., Sun X., Xiao R., Zhou L., Gao X., Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 2012, 419:274-280.
39. Li J., Chen H., Mariani A., et al. HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int J Mol Sci 2013, 14:6026-6043.
40. LeBleu V.S., Teng Y., O'Connell J.T., et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med 2013, 19:227-231.
41. Plebani M. HE4 Study Group. HE4 in gynecological cancers: report of a European investigators and experts meeting. Clin Chem Lab Med 2012, 50:2127-2136.
42. Bignotti E., Ragnoli M., Zanotti L., et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011, 104:1418-1425.
43. Zanotti L., Bignotti E., Calza S., et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med 2012, 50:2189-2198.
44. Kalogera E., Scholler N., Powless C., et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol 2012, 124:270-275.
45. Moore R.G., Brown A.K., Miller M.C., et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008, 110:196-201.
46. Yurkovetsky Z., Skates S., Lomakin A., et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010, 28:2159-2166.
47. Bingle L., Cross S.S., High A.S., et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006, 7:61-71.
48. Kamei M., Yamashita S., Tokuishi K., et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res 2010, 30:4779-4783.
49. Tokuishi K., Yamashita S., Ohbo K., Kawahara K. Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma. Tumour Biol 2012, 33:103-109.
50. Yamashita S., Tokuishi K., Hashimoto T., et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 2011, 32:265-271.
51. Iwahori K., Suzuki H., Kishi Y., et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol 2012, 33:1141-1149.
52. Yamashita S., Tokuishi K., Moroga T., et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumour Biol 2012, 3:2365-2370.
53. Nagy B., Bhattoa H.P., Steiber Z., et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clin Chem Lab Med 2014, [Epub ahead of print]. 10.1515/cclm-2014-0041.
54. Hellström I., Heagerty P.J., Swisher E.M., et al. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett 2010, 296:43-48.
55. Macuks R., Baidekalna I., Donina S. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case-control study. Asian Pac J Cancer Prev 2012, 13:4695-4698.
56. Hellström I., Swisher E., Hellström K.E., Yip Y.Y., Agnew K., Luborsky J.L. Anti-HE4 antibodies in infertile women and women with ovarian cancer. Gynecol Oncol 2013, 130:629-633.
57. Hellström I., Hellström K.E. Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. Expert Opin Med Diagn 2011, 5:227-240.
58. Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol 2012, 33:141-148.
59. Moore R.G., Miller M.C., Eklund E.E., Lu K.H., Bast R.C., Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012, 206(349):e1-e7.
60. Bjerner J., Høgetveit A., Wold Akselberg K., et al. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study. Scand J Clin Lab Invest 2008, 68:703-713.
61. Stockley R.A., Shaw J., Whitfield A.G., Whitehead T.P., Clarke C.A., Burnett D. Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions. Thorax 1986, 41:17-24.
62. Anastasi E., Granato T., Marchei G.G., et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010, 31:411-415.
63. Zuckerman E., Lanir A., Sabo E., et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999, 94:1613-1618.
64. Liu W., Yang J., Chi P.D., et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis 2013, 17:1346-1353.
65. Cases A., Filella X., Molina R., Ballesta A.M., Lopez-Pedret J., Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991, 57:183-186.
66. Molina R., Navarro J., Filella X., Castel T., Ballesta A.M. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 2002, 23:39-44.
67. Bruun L., Björk T., Lilja H., Becker C., Gustafsson O., Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant 2003, 18:598-603.
68. Yilmaz H., Gürel O.M., Celik H.T., et al. CA125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis. Ren Fail 2014, 36:210-216.
69. Nagy B., Krasznai Z.T., Balla H., et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem 2012, 49:377-380.
70. Frankel W.L., Herold D.A., Ziegler T.W., Fitzgerald R.L. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996, 106:118-123.
71. Wayand D., Baum H., Schätzle G., Schärf J., Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem 2000, 46:1345-1350.
72. Gerhardt W., Ljungdahl L. Troponin T: a sensitive and specific diagnostic and prognostic marker of myocardial damage. Clin Chim Acta 1998, 272:47-57.
73. Maries L., Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr 2013, 24:286-289.
74. Gizzo S., Ancona E., Saccardi C., D'Antona D., Nardelli G.B., Plebani M. Could kidney glomerular filtration impairment represent the "Achilles heel" of HE4 serum marker? A possible further implication. Clin Chem Lab Med 2014, 52:e45-e46.
75. Kuster N., Cristol J.P., Cavalier E., et al. Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation. Clin Chim Acta 2014, 428:89-95.
76. Su Z., Graybill W.S., Zhu Y. Detection and monitoring of ovarian cancer. Clin Chim Acta 2013, 415:341-345.
77. Angioli R., Miranda A., Aloisi A., et al. A critical review on HE4 performance in endometrial cancer: where are we now?. Tumour Biol 2014, 35:881-887.
78. Melichar B. Human epididymis protein 4: the start of a post-ROMAn era?. Clin Chem Lab Med 2012, 50:2069-2073.
79. Davidson B., Tropé C.G., Reich R. The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol 2014, 133:640-646.